Smarter leaders trust GlobalData

Data Insights Genomics in pharma: anti-sense oligonucleotides

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

F. Hoffmann-La Roche Ltd

Alnylam Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Arbutus Biopharma Corp

Silence Therapeutics Plc

View all

According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Anti-sense oligonucleotides is a key innovation area in genomics

Anti-sense oligonucleotides are synthetic, single-stranded strands of DNA or RNA sequences that can bind to complementary target RNA sequences, leading to the degradation or inhibition of translation of the target RNA. By targeting specific RNA sequences, anti-sense oligonucleotides can modulate gene expression and have potential therapeutic applications in treating various diseases.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 285+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-sense oligonucleotides.

Key players in anti-sense oligonucleotides – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to anti-sense oligonucleotides

Ionis Pharmaceuticals (Ionis) is one of the leading patent filers in anti-sense oligonucleotides. Formerly known as ISIS Pharmaceuticals, Ionis focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical development. It develops products based on its proprietary antisense technology. The company partners with other pharmaceutical companies to develop a range of products in different therapeutic areas. F. Hoffmann-La Roche and Alnylam Pharmaceuticals are some of the other key patent filers in anti-sense oligonucleotides.

In terms of application diversity, AptaBio Therapeutics leads the pack, while Johnson & Johnson and EdiGene stood in the second and third positions, respectively.

By means of geographic reach, the Novartis held the top position followed by Pfizer and Dynavax Technologies.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Genomics.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.